Optimal management of hepatorenal syndrome in patients with cirrhosis.

about

Treatment and management of ascites and hepatorenal syndrome: an update Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis.Development of a rat model of D-galactosamine/lipopolysaccharide induced hepatorenal syndrome.

P2860

Q27000268-BD7DED35-DAB7-49DC-8E33-147837FCF341 Q35852815-0B802729-FCA1-46C0-B2BA-753957A649B1 Q43197363-ADD1B499-1991-4714-AAB9-AE4EBD4FC1C7

P2860

Optimal management of hepatorenal syndrome in patients with cirrhosis.

Item

http://www.wikidata.org/entity/Q38173738

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Optimal management of hepatorenal syndrome in patients with cirrhosis.

@en

type

Item

label

Optimal management of hepatorenal syndrome in patients with cirrhosis.

@en

prefLabel

Optimal management of hepatorenal syndrome in patients with cirrhosis.

@en

P1476

Optimal management of hepatorenal syndrome in patients with cirrhosis

@en

P2093

Filippo Morando

http://www.w3.org/2001/XMLSchema#string

Paolo Angeli

http://www.w3.org/2001/XMLSchema#string

P2860

TIPS versus paracentesis for cirrhotic patients with refractory ascites

Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial

Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis

Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data.

Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis.

Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man?

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.

Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.

Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.

Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial.

P304

87-98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/HMER.S6918

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24367209

http://www.w3.org/2001/XMLSchema#string

P932

3846372

http://www.w3.org/2001/XMLSchema#string

Optimal management of hepatorenal syndrome in patients with cirrhosis.

about

P2860

P2860

Optimal management of hepatorenal syndrome in patients with cirrhosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932